Drugs developed by Alphabet’s drug discovery subsidiary and designed by artificial intelligence are expected to head to trial by the end of the year, according to a Google (GOOGL) executive.

When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...

New York, New York-- (Newsfile Corp. - January 22, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against BioAge Labs, Inc. (NASDAQ: BIOA) and ...

An Alphabet-backed startup is poised to begin clinical trials of its first artificial intelligence-designed drug by year-end.

Google DeepMind spinoff Isomorphic Labs expects research of drugs it designed using artificial intelligence will begin this ...

New York, New York-- (Newsfile Corp. - January 20, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against BioAge Labs, Inc. (NASDAQ: BIOA) and ...

NDAQ:BIOA) ROSEN, A LEADING LAW FIRM, Encourages BioAge Labs, Inc. Investors to Secure Counsel Before Important Deadline in ...

N-Power Medicine, backed by Merck GHI, announced the acquisition of Syapse Holdings. Samsung Biologics and LigaChem extended their ADC services deal. Publicis Worldwide merged with Leo Burnett to form ...

BioSpace recaps 2024’s top venture capital rounds in biopharma, from Xaira Therapeutics’ blockbuster $1B raise to ...

Metsera (MTSR), which is developing ultra-long-acting drugs for obesity, has filed for a $100M initial public offering. Read more here.

Kristin Sherman leads startup Kovina Therapeutics, which is still in the early stages of developing ways to stop human ...

Eli Lilly and venture capital firm Andreessen Horowitz (a16z) are joining forces to create a unique new fund dubbed the ...